- New ETFs
- Bond ETFs
- Currency ETFs
- Emerging Market ETFs
- Commodity ETFs
- Broad U.S. Equity ETFs
- Sector ETFs
- Specialty ETFs
Biogen Idec Inc (Nasdaq: BIIB) Posts Strong Earnings Growth
Recent Articles by Daniel Hayden IV
- Goldman Sachs Reiterates Federated Investors (FII) Sell Rating
- Stern Agee Raises Shoe Carnival (SCVL) Price Target To $27
- Stern Agee Initiates Bed Bath & Beyond (BBBY) With Neutral Rating
- Stifel Nicolaus Maintains Invesco Mortgage Capital (IVR) Hold Rating
- Craig-Hallum Maintains LookSmart (LOOK) Buy Rating
Company News
- Tiffany Reports Earnings Monday Morning (TIF)
- Carl Icahn Makes Hostile Takeover Bid For Lions Gate Entertainment (LGF)
- Ex-Cadbury Executive To Head Kraft’s Confectionery Unit (KFT)
- Morningstar Acquires Realpoint LLC (MORN)
- Pfizer Eyes German Drug Maker Stada (PFE, TEVA)
General
- Court Asks Fed To Disclose Records Of $2 Trillion U.S. Loan Program Launched After Lehman Collapse (OPY)
- Potential Reversals 3/19/10
- Coal Prices Ready To Burn Hot In 2010?
- Bear Flag On Chart Looks Promising..But Volume Could Stall It. (NASDAQ:QQQQ), (NYSE:SPY), (NYSE:DIA)
- Markets Tank On Healthcare Uncertainty, Options Expiration. (NASDAQ:GOOG), (NASDAQ:BIDU), (NYSE:BA)
Earnings
- Tiffany Reports Earnings Monday Morning (TIF)
- Top Performing Industries For March 19 (CNC, HANS, CAJ, BBY, GENT)
- CTAS Well Positioned To Pursue Acquisitions
- Stocks That Created New 52-Week Highs (LOPE, HBOS, HDSN, ITMN, INET)
- Benzinga’s Volume Movers (CTEL, IPSU, HANS, TEVA, TRMB)
Movers
- Energy ETF Under Pressure (XLE)
- Healthcare ETF Close To Going Green (XLV)
- Teva Pharmaceutical Moving On High Volume Again (TEVA)
- Bear Flag On Chart Looks Promising..But Volume Could Stall It. (NASDAQ:QQQQ), (NYSE:SPY), (NYSE:DIA)
- Benzinga’s Volume Movers (CTEL, IPSU, HANS, TEVA, TRMB)
Markets
Posted on 02/09/10 at 10:42am by Daniel James Hayden IV
Biotech company Biogen Idec Inc (Nasdaq: BIIB) reported a rise in 4th quarter earnings and revenue.
Biogen Idec Inc said that it earned $306 million, or $1.06 per share, compared with $207 million, or 70 cents per share, for the same quarter a year earlier. Revenue for the 4th quarter was up 5% to $1.13 billion.
Excluding various one time charges, Biogen Idec would have posted adjusted earnings of $1.20 per share versus 93 cents per share a year earlier.
According to a poll of analysts by FactSet Research, Biogen Idec was expected to earn $1.05 per share, on revenue of $1.11 billion.
A 40% jump in sales of Biogen Idec's new multiple sclerosis drug Tysabri, was a factor in the company's strong earnings growth.
Bookmark/Search this post with:
Related Articles
Today's Trading Ideas
Featured Articles
Related News from the Stock Market
There are 0 comments
Please note that comments may take up to one hour before they get published on the site. Please check back later to see your comments.
Post new comment
Receive Benzinga's Best 2010 Stock Idea!
